The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs lowers price target for tandem diabetes care to thirty five dollars
UBS has lowered its price target on Tandem Diabetes Care to $35 from $40 while maintaining a neutral rating. The company specializes in advanced insulin delivery systems, including the Tandem Mobi and t:slim X2 insulin pumps, both featuring Control-IQ technology for automated insulin delivery. These pumps are compatible with various infusion sets and can be updated via software, enhancing user experience and glycemic control.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.